UIHC PET IMAGING is a pharmaceutical company focused on Oncology, Neurology. Key products include GALLIUM GA 68 EDOTREOTIDE.
UIHC PET IMAGING's Key Drugs
UIHC PET IMAGING's core commercial portfolio centers on GALLIUM GA 68 EDOTREOTIDE, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.
UIHC PET IMAGING's Recent FDA Approvals
New NDA/BLA approvals for UIHC PET IMAGING over the last two years — novel drugs only, excluding generics and label supplements.
UIHC PET IMAGING's Therapeutic Areas
UIHC PET IMAGING's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UIHC PET IMAGING's Top Competitors
UIHC PET IMAGING's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UIHC PET IMAGING Pipeline Snapshot
Active clinical trials for UIHC PET IMAGING across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GALLIUM GA 68 EDOTREOTIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-08-06
- Latest
- 2023-07-27
- Applications
- 3